tbuckley/cabot-search huggingface dataset:
1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Authors: M. Ruiz Vico, D. Wetterskog, S. Thakali, F. Orlando, A.K. Jayaram, O. Vainauskas, D.E. Castellano Gauna, K.D. Martins, K. Iwata, G. Gourgioti, A. Serikoff, L. Astrom, V. Matveev, A.A. Esen, S. Feyerabend, E. Senkus-Konefka, S. Gupta, A.S. Merseburger, F. Demichelis, G. Attard
Journal: Annals of Oncology (2023)
194P Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
Authors: D. Barth, F. Moik, S.M. Steinlechner, F. Posch, V. Schlintl, L. Koch, N. John, R. Wurm, M. Pichler, T. Bauernhofer, P. Reimann, C. Wohlkönig, E. Richtig, T. Winder, M. Preusser, P.J. Jost, C. Ay, A. Gerger, A. Terbuch, J.M. Riedl
Journal: Annals of Oncology (2023)
172P T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Authors: N. Zungsontiporn, S. Santisukwongchote, P. Sitthideatphaiboon, N. Leelayuwatanakul, K. Korphaisarn, P. Chantranuwat, V. Sriuranpong, C. Vinayanuwattikun
Journal: Annals of Oncology (2023)
162P MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Authors: A.L. Sanchez Iglesias, V. Morillo Macías, A. Nogué Infante, M. Domingo, V. Aznar, R. Yebana, C. Puerto Frances, A. Fuster-Matanzo, P. Plaza Ortega, F. Bellvis Bataller, R. Muelas Soria, A. Alberich Bayarri, C. Ferrer Albiach
Journal: Annals of Oncology (2023)
1857P Psychological distress in Georgian cancer patients undergoing chemotherapy: Before and after the COVID-19 pandemic
Authors: M. Abuladze, K. Saganelidze, T. Melkadze, E. Mariamidze, N. Otkhozoria, S. Tsitsilashvili, M. Katcharava, E. Kekelia, B. Tchatchiashvili, I. Kipiani, T. Esakia
Journal: Annals of Oncology (2023)
1837P Assessing PSA
Authors: S. Halabi, A. Roy, S. Guo, L. Rydzewska, P.J. Godolphin, M.K. Parmar, M. Hussain, C. Tangen, I.M. Thompson, M.A. Carducci, M.R. Smith, M.J. Morris, G. Gravis, D. Dearnaley, P. Verhagen, T. Goto, N.D. James, M.E. Buyse, J. Tierney, C. Sweeney
Journal: Annals of Oncology (2023)
1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Authors: J.S. de Bono, S.K. Sandhu, K. Fizazi, J. Sun, A. Ward, E.S. Antonarakis
Journal: Annals of Oncology (2023)
175P Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Authors: P. Mutha, F. Duan, V.S. Viswanathan, M. Khorrami, N. An, V. Velcheti, A. Gupta, S.S. Ramalingam, K. Kelly, K. Sandler, H. Borghaei, A. Madabhushi
Journal: Annals of Oncology (2023)
1827P Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Authors: D.J. George, K. Ramaswamy, H. Yang, Q. Liu, A. Zhang, A. Greatsinger, J. Ivanova, B. Thompson, B. Emir, A. Hong, S.J. Freedland
Journal: Annals of Oncology (2023)
171P Combined expression of MKI67, FOXC1 and PDL1 is a pan-tumor tissue-agnostic predictor of PD1/PDL1 inhibitor efficacy in metastatic renal cell cancer: Validation in checkmate 009, 010 and 025 clinical trial cohorts
Authors: P.S. Ray, T. Ray, C. Taylor, R. Hussa
Journal: Annals of Oncology (2023)
1851P Psychological well-being of patients with colorectal cancer during the third wave of the COVID-19 pandemic: Results from cohort II of the PICO-SM study
Authors: K.V. Kamposioras, K. Dadouli, P. Ntellas, K.H.J. Lim, M. Adamou, D. Anderson, L. Simpson, A. Shanthappa, M. Braun, J. Barriuso, J. Connell, J. Williams, D. Lehwald, J. Hasan, S. Mullamitha, K. Marti, M.P. Saunders
Journal: Annals of Oncology (2023)
1839P Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Authors: G. Seed, S. Greening, J. Goodall, J. Rekowski, R. Christova, N. Mehra, M. Eisenberger, K. Fizazi, B. Tombal, C. Wülfing, C.N. Sternberg, D.E. Castellano Gauna, S. Oudard, O. Sartor, C. Geffriaud-Ricouard, M. Chadjaa, S. Mace, S. Carreira, W. Yuan, J.S. de Bono
Journal: Annals of Oncology (2023)
1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
Authors: S.T. Tagawa, J. Shen, L. Skidmore, J. Nelson, R. Pachynski, S. Zhang
Journal: Annals of Oncology (2023)
200P Precise tumor &amp; patient selection for CDR404: A bispecific &amp; bivalent MAGE-A4 T cell engager
Authors: G. Giacomazzi, M. Liivrand, R. Hieta, N. Dupuis, D. Rondas, P. Swatkowski, M. Vrohlings, D. Lenherr-Frey, L. Borras, S. Biswas, R. Leidner, E. Calvo
Journal: Annals of Oncology (2023)
203P Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Authors: R.D. Gentzler, N. Sharma, A. Mitra, R. Ben-Shachar, M. Stein, J. Guinney, H. Nimeiri, W. Iams, C. Aggarwal, J. Patel
Journal: Annals of Oncology (2023)
186P Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials
Authors: M. Tagliamento, M. Bruzzone, M. Ceppi, C. Genova, F.G. Dall'Olio, M. Aldea, F. Spagnolo, E. Blondeaux, F. Poggio, M. Brandão, J. Remon Masip, L. Del Mastro, L. Hendriks, F. Barlesi, D. Planchard, M. Lambertini, B. Besse
Journal: Annals of Oncology (2023)
187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Authors: C.E. Heilig, M. Singh, M-V. Teleanu, A. Desuki, T. Kindler, M. Bitzer, B.D. Baier, V. Kunzmann, N. von Bubnoff, H. Süsse, L. Heiligenthal, K. Steindorf, A. Benner, S. Kreutzfeldt, C. Heining, P. Horak, D. Hübschmann, H. Glimm, S. Fröhling, R.F. Schlenk
Journal: Annals of Oncology (2023)
1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Authors: A.A. Azad, V.R. Lincha, M. Hadigol, J. Hoffman, N. Agarwal, N. Matsubara, Y. Wang, L. DeAnnuntis, F. Zohren, D. Wang
Journal: Annals of Oncology (2023)
192P Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Authors: H. Sweiti, L. Demirdjian, S. Triantos, K. Standish, S. Thomas, J. Greshock, Q. Xia, J. Paone, P. Sheridan, S. Pant, C. Massard, D.A. Reardon, Y. Loriot, M.H.H. Schuler
Journal: Annals of Oncology (2023)
202P Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Authors: N. Papadopoulos, A.M. Lennon, P. Elias, S. Rego, O. Choudhry, D. Flake, J. Cohen, C. Douville, A. Honushefsky, I. Kinde, A. Klein, Z. Salvati, C. Tomasetti, E. Wagner, C. Walter, E. Fishman, K. Kinzler, B. Vogelstein, T.M. Beer, A. Buchanan
Journal: Annals of Oncology (2023)
1838P Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
Authors: X.X. Wei, K.N.N. Chi, J.S. de Bono, K. Fizazi, B. Krause, K. Herrmann, K. Rahbar, S.T. Tagawa, M.J. Morris, A. Meisel, G. Holder, O. Mirante, J. Wu, O. Sartor
Journal: Annals of Oncology (2023)
199P Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Authors: L. Sharma, S. Choi, V. Balaji, A. Joshi, I. Mporas, J. Shi, Y. Zhao, V. Tailor, G. Powell, D. Alrifai, R. Shah, J.S.C. Waters, O.M. Adeleke
Journal: Annals of Oncology (2023)
158P In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Authors: A. Gonzalez-Vilanova, T.C. Fleitas, L. Gaba Garcia, S. Zuniga-Trejos, J.A. Perez Fidalgo
Journal: Annals of Oncology (2023)
1826P Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial
Authors: E.F. Giunta, M. Sansovini, I. Grassi, I. Marini, N. Brighi, C. Lolli, G. Schepisi, S. Nicolini, F. Foca, M. Monti, M. Celli, P. Caroli, V. Di Iorio, A. Sarnelli, S. Severi, G. Paganelli, F. Matteucci, U.F.F. De Giorgi
Journal: Annals of Oncology (2023)
151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
Authors: E.F. Smit, E. Felip, D. Uprety, M. Nagasaka, K. Nakagawa, L. Paz-Ares, J. Pacheco, B.T. Li, D. Planchard, C.S. Baik, Y. Goto, H. Murakami, K.M.C. Pereira, A. Taguchi, M. Kogo, Y. Kuwahara, M. Zou, W. Feng, Z. Tsuchihashi, P.A. Jänne
Journal: Annals of Oncology (2023)
189P Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test
Authors: C. Douville, L. Hogstrom, V. Gainullin, H.J. Hwang, S. Chowbina, Y. Zhang, M. Gray, C. Nobles, M. Kumar, M. Manesse, F. Zhuang, V. Fa, X. Chen, J. Garces, A. Mcelhinny, G. Cerqueira, G.A. Silvestri, S. Rego, T.M. Beer, F. Diehl
Journal: Annals of Oncology (2023)
163P Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Authors: J. Bar, M.R. Sharma, Y. Kuboki, R. Perets, D. Sommerhalder, N. Yamamoto, J. Powderly, J.H. Strickler, M. Li, A. Luo, G. Morrison-Thiele, M.R. Neagu Aristide, A. Vasilopoulos, D.R. Camidge
Journal: Annals of Oncology (2023)
1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Authors: S.K. Sandhu, G. Gotto, F.E. Vera-Badillo, S-S. Byun, H.J. Cutuli, A.J.P.D.S. Gomes, C. Helissey, L.I. Karsh, A. Peer, D.D. Preto, Y-S. Pu, R. Ravilla, G. Roubaud, I.A. Skoneczna, W. Kim, B. Espina, M. Withelder, K. Urtishak, P.S.J. Francis, F. Saad
Journal: Annals of Oncology (2023)
145P Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence
Authors: F. Angileri, M. Kindermans, V.K. Attignon, M. Afshar, J-Y. Blay, J. Boulahfa, S. Boyault, S. Chabaud, G. Clave, G. Garin, F. Parmentier, D. Perol, E. Sohier, T. Turcat, O. Tredan, A. Viari, P. Saintigny
Journal: Annals of Oncology (2023)
1852P Mental health among Tunisian oncologists
Authors: N. Issaad, Y. Zenzri, None I. lasmer, H. Ben Mansour, K. Meddeb, N. Chraiet, F. Letaief-Ksontini, H. Rais, A. Mokrani, M. Ayadi, A. Mezlini
Journal: Annals of Oncology (2023)
1840P RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Authors: J. Carmichael, I. Figueiredo, B. Gurel, W. Yuan, J. Rekowski, G. Seed, S. Carreira, C. Bertan, N. Beije, D. Westaby, C. Guo, A. Neeb, J. Welti, L. Gallagher, D. Bogdan, M. Crespo, R. Riiisneas, C. Lord, A. Sharp, J.S. de Bono
Journal: Annals of Oncology (2023)
182P ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset
Authors: W. Iams, R. Ben-Shachar, L. Gai, K. Beauchamp, N. Sharma, S. Islam, J. Guinney, H. Nimeiri, R.D. Gentzler, E. Cohen
Journal: Annals of Oncology (2023)
204P Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Authors: J. Choi, A. Fellowes, E. Pikarsky, M. Teixeira, I. Vogl, A. Ahmed, K. Bi, K. Kirkconnell, C. Yin, M. Shin, N. Shrestha, J. Blau, S. Li, Y. Li, G. Kumar, R. Chien, S.E. Trabucco, W. Wen, M. Javey, Z. Li
Journal: Annals of Oncology (2023)
160P Real-world practices and physician perspectives on biomarker testing and treatment patterns in patients with locally advanced unresectable or metastatic (La/m) gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in the US
Authors: K. Lewis, R. Fuldeore, S. Braun, G. Gourgioti, A. Lambert, G. Thomason, K. Bernacki, J. Yang
Journal: Annals of Oncology (2023)
201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Authors: L. Decoster, P.G. Aftimos, S. Rottey, H. Prenen, J.J. Collignon, J. Mebis, J-L. Canon, V. Fastenaekels, N. Cappoen, S.R. Joris, J. De Grève
Journal: Annals of Oncology (2023)
152P Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study
Authors: S.R. Joris, H. Denys, J.J. Collignon, M. Rasschaert, D. T'Kint de Roodenbeke, F.P. Duhoux, J-L. Canon, S. Tejpar, J. Mebis, L. Decoster, P.G. Aftimos, J. De Grève
Journal: Annals of Oncology (2023)
1850P The effectiveness of a CBT-based mobile application for the mental state of women with breast cancer
Authors: M. Haneczok, E. Wojtyna, M. Jarzab, R. Matkowski, A. Syska-Bielak, A. Kołodziejczyk, M. Pawełczak-Szastok, Z. Kurasz, M. Krzyżowski, M. Ostrowski
Journal: Annals of Oncology (2023)
157P CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Authors: P. Yu, Y. Cao, X. Chen, W. Wu, Q. Xu, J. Fang, X. Huang, X. Shi, W. Zhizheng, Z. Ye, F. Pang, Y. Du, X. Cheng
Journal: Annals of Oncology (2023)
169P Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Authors: N. Zhang, Y. Xiang, Z. Jing, F. Yu, J. Zeng, X. Pan, W. Zhou, X. Liang, Y. Yue, H. Zhang, Y. Deng, S. Deng, S. Mo, X. Jiang, X. Zeng
Journal: Annals of Oncology (2023)
1843MO The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial)
Authors: F. Wu, Y. Zeng, Y. Li, J. Liu, C. Xiao, M. Liu, Z. Qiu, C. Deng, F. Ma, C. Xia, B. Zhang, Z. Xiao, C. Xu, Z. Sheng, P. Liu, X. Zeng, Y. Zhao, J. Zhou, None X. liu, C. Hu
Journal: Annals of Oncology (2023)
141P Microsatellite instability and its relationship with systemic inflammation as prognostic factors in localised colorectal cancer
Authors: J.H. Yeo, J.H. Park, H.K. Ahn, I. Park, Y.S. Kim, E.K. Cho, D. Shin, W-S. Lee, J.H. Baek, S.J. Sym
Journal: Annals of Oncology (2023)
138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations
Authors: M. Polito, C. Le Tourneau, A. DeMontfort, S. Cousin, M. Toulmonde, C.A. Gomez-Roca, K. Bourcier, I. Korakis, F. Bertucci, E. Mitry, C. Mazza, P. Cassier, C. Coutzac, A. Italiano, V.K. Attignon, R. Mayet, D. Perol, M.P. Sablin, J-Y. Blay, O. Tredan
Journal: Annals of Oncology (2023)
131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort
Authors: M. Rübsam, M. Rheinnecker, B. Hutter, M. Fröhlich, C.E. Heilig, N. Paramasivam, M. Oleś, C. Ball, H. Glimm, M. Hlevnjak, M. Zapatka, P. Lichter, S. Fröhling, R.F. Schlenk, D. Hübschmann
Journal: Annals of Oncology (2023)
375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Authors: L. Cavalcante, L.L. Siu, J. Toso, D. Mires, R. Shiga, J. Maruca, G. Ayele, P. Kumar Vuppala, Y. Cheng, L. Huang, J.E. Connolly, Y. Ishimoto, M. Sue, P.L. Bedard
Journal: Annals of Oncology (2023)
352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Authors: C. Vernieri, F. Ligorio, M.V. Dieci, M. Lambertini, C. De Angelis, M. Iorfida, A. Botticelli, C. Strina, A. Vingiani, L. Provenzano, G.V. Bianchi, S. Folli, D. Generali, A. Zambelli, S. de Placido, L. Del Mastro, V. Guarneri, G. Capri, G. Pruneri, F.G.M. De Braud
Journal: Annals of Oncology (2023)
1871P The PainRELife ecosystem: A new aid for improving clinical care and shared decision-making in breast cancer patients with chronic pain
Authors: M. Masiero, C. Filipponi, C. Marzorati, E. Munzone, None L. guido, V. Guardamagna, S. Marceglia, A.M. Caruso, V. Manzelli, C. Savino, C. Conti, F. Rizzi, G. Candiani, F. Memini, L. Chiveri, M. Corbo, A. Milani, E. Fragale, F. Didier, G. Pravettoni
Journal: Annals of Oncology (2023)
135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)
Authors: R.A. Watson, O. Tong, C. Taylor, G. Vallance, F. Matos Santo, M. Little, B. Sun, B. Shine, M.R. Middleton, N.A. Coupe, M. Payne, B.P. Fairfax
Journal: Annals of Oncology (2023)
2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
Authors: A. Necchi, J.W.F. Catto, T.B. Powles, F. Guerrero-Ramos, G. Simone, N.D. Shore, J. Salinas, A.S. Merseburger, M. Roumiguié, H. Kitamura, D. Morris, Q. Wei, F. Korkes, M. Hasan, S. Jin, J. Maffeo, C. Hammond, H. Sweiti, R. Somer, S.S. Chang
Journal: Annals of Oncology (2023)
1872P Financial distress of a cancer disease in Germany: A new patient reported outcome measure (PROM) and first results from a bi-centered cross-sectional analysis
Authors: S. Pauge, L. Richter, A. Züger, K. Mehlis, V. Mathies, T. Ernst, W. Greiner, N. Menold, E.C. Winkler
Journal: Annals of Oncology (2023)
132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
Authors: M. Morfouace, J. Oliveira, N. Penel, J. Peron, M. Pracht, B. Brasiuniene, A. Capela Marques, C. Gennigens, L. Greillier, M-S. Robert, H.J. Klumpen, R. Peeters, L.F.L. Licitra, N. Girard, J.A. Gietema, W. de Herder, E. Kapiteijn, A. Idbaih, I.L. Ray-Coquard, J-Y. Blay
Journal: Annals of Oncology (2023)

Background: Assessing the functional state of homologous recombination repair (HRR) is crucial to predict an effective response to PARP inhibitor (PARPi) treatment or platinum-based chemotherapy in cancer patients.Drug approvals are currently mostly based on mutations in BRCA1 and BRCA2 or genomic scarring alone.Composite biomarkers may extend the discriminative power and make targeted treatment approaches available to a wider range of patients and entities.Methods: Whole-genome or -exome sequencing (WGS or WES) data from 739 patients including various rare cancers were evaluated for germline and somatic alterations in one of 183 genes related to HRR as well as for genomic patterns of HRR deficiency (HRD), i.e. exposure to single-base substitution signature 3, quantification of HRD-derived loss of heterozygosity (LOH-HRD), and the number of large-scale state transitions (LST).The individual markers were integrated into a composite biomarker, the TOP-ART score, with a scoring system (0-7) and compared to the other published HRR biomarkers.Currently, this biomarker is used to determine eligibility for the TOP-ART trial (ClinicalTrials.govidentifier: NCT03127215, olaparib/trabectedin vs. physician's choice, estimated study completion: December 2023). Results:The occurrence and severity of HRD predicted by the TOP-ART score varies between entities.Strong associations were found between genomic patterns of HRD and mutations affecting several genes, including but not limited to BRCA1 and BRCA2.The phenotypic susceptibility to BRCA1 and BRCA2 impairment varies between entities and depends on zygosity.TOP-ART score positivity (score 3; 312 cases) overlaps with but is more inclusive than HRDetect (55 cases) and CHORD (26 cases).In particular, we identify patients who were biomarker-negative for HRDetect and CHORD, but positive in the TOP-ART score, and achieved long-lasting disease control upon treatment with olaparib/trabectedin. Conclusions:The TOP-ART score is a novel composite HRR biomarker developed and validated in an observational precision oncology cohort.It has the potential to broaden access to targeted treatments and is prospectively used to determine eligibility for the TOP-ART trial.Clinical trial identification: NCT03127215 Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603) Estimated
351TiP EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Authors: E. Buhrer, E. Xenophontos, A-S. Hamy-Petit, J. Casas, C. Callens, A. Lanzi, T. Meyskens, C. Poncet, E.G.C. Brain
Journal: Annals of Oncology (2023)
1860P Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)
Authors: N. Vanlaer, I. Dirven, M. Vounckx, J. Tijtgat, M. Verhaert, S. Aspeslagh, L. Decoster, A. Rogiers, B. Neyns
Journal: Annals of Oncology (2023)
1869P First impressions: A prospective evaluation of patient comprehension and satisfaction in the communication of diagnosis, treatment, and prognosis following the initial medical oncology consultation
Authors: Y. Bach, E.D. Panov, O. Espin-Garcia, E. Chen, M.K. Krzyzanowska, G.M. O'Kane, M. Moore, R. Prince, J. Knox, R. Grant, L. Ma, M. Allen, L. Eng, T. Megid, R.W-J. Jang, E. Elimova
Journal: Annals of Oncology (2023)
1204TiP Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Authors: N. Belani, P. Ghatalia, T. Cohen, P. Ehrlichman, D. Faller, R. Iyer, A. Limon, H. Soares, J. Whetstine, H. Borghaei, N. Vijayvergia
Journal: Annals of Oncology (2023)
136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Authors: Y. Mao, X. Wu, N. Xu, Y. Bai, D. Wang, X. Chen, X. Yin, Y. Deng, J. Yang, J. Zhang, J. Tang, Y. Huang, J. Li, M. Xu, N. Li, Y. Mao, A. Gozman, J. Xu
Journal: Annals of Oncology (2023)
2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
Authors: S. Gupta, O. Alhalabi, A. Bamias, J. Bellmunt, D.E. Castellano Gauna, J. Bedke, T. Friedlander, B. Garmezy, P. Grivas, R.A. Huddart, A. Necchi, T.B. Powles, J. Puente, D.A.R. Da Rosa, F. Wang, C. Lambertini, A. Andreev-Drakhlin, M. Fasso, Y. Loriot
Journal: Annals of Oncology (2023)
2029TiP Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Authors: S. Chandana, B. Garmezy, A. Dowlati, M.R. Sharma, W. Henner, R. Robinson, P. Hingorani, E. Jeng, K.P. Papadopoulos
Journal: Annals of Oncology (2023)
137P VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801
Authors: C.A. Gomez-Roca, P. Fons, P-B. Ancey, P. Cassier, J-P. Delord, L. Davenne, M. Fitzgerald, M. Mandron, M.R. Paillasse, J. Friend, P. Rochaix
Journal: Annals of Oncology (2023)
142P Correlating total tumor volume on CT-Scan and liquid biopsy ctDNA in 1017 patients with metastatic cancer: A novel study
Authors: Y. Belkouchi, L. Dawi, L. Lawrance, S. Ammari, D. Vasseur, F. Wirth, O. Gautier, P-H. Cournede, J. Hadchiti, C. David, F. Bidault, C. Balleyguier, M. Kind, None H. Talbot, A. Italiano, N. Lassau
Journal: Annals of Oncology (2023)
1912TiP STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Authors: S.K. Pal, T.B. Powles, R. Kanesvaran, C-H. Lee, M. Liu, Z. Wang, A. Bhatt, P. Patel, C. Suarez Rodriguez
Journal: Annals of Oncology (2023)